KIF14 in cancer biology: implications for diagnosis and therapy

Ashok Kumar Bishoyi1, Shaker Al-Hasnaawei2,3, Subbulakshmi Ganesan4

  • 1Department of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, India. ashokkumarbishoyi2@gmail.com.

PubMed

Insights

Kinesin family member 14 (KIF14) is overexpressed in many cancers, driving tumor growth and resistance to therapy. Targeting KIF14 offers a promising strategy for treating aggressive and hard-to-treat malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Kinesin family member 14 (KIF14) is a motor protein vital for cell division and intracellular transport.
  • KIF14 overexpression is linked to poor prognosis and therapy resistance in multiple cancers.
  • Its specific roles in cancer progression require comprehensive analysis.

Purpose of the Study:

  • To review the involvement of KIF14 in cancer progression.
  • To explore the molecular mechanisms of KIF14's tumorigenic effects.
  • To evaluate KIF14 as a prognostic biomarker and therapeutic target.

Main Methods:

  • Comprehensive literature review of oncological studies on KIF14.
  • Analysis of KIF14's role in cell cycle regulation and mitotic spindle formation.
  • Exploration of KIF14's involvement in oncogenic signaling pathways.

Main Results:

  • KIF14 overexpression is a common feature in breast, ovarian, lung, liver, and brain cancers.
  • KIF14 contributes to tumor aggressiveness, poor clinical outcomes, and therapeutic resistance.
  • Its functions are implicated in cell cycle dysregulation and aberrant mitotic spindle assembly.

Conclusions:

  • KIF14 is a significant driver of tumor growth and metastasis.
  • KIF14 holds potential as a prognostic biomarker for cancer patients.
  • Targeting KIF14 presents a promising therapeutic avenue for aggressive cancers.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K